Showing 2501-2510 of 3223 results for "".
- NIH: New Technique Enhances Quality Control of Lab-Grown Cells for AMD Treatmenthttps://modernod.com/news/nih-new-technique-enhances-quality-control-of-lab-grown-cells-for-amd-treatment/2482074/Researchers at the National Eye Institute (NEI) say they have improved a crucial step in the production of retinal pigment epithelium (RPE) they are testing in a clinical trial as treatment for age-related macular degeneration (AMD). Their technique combines electrochemical cell measurements
- DigitalOptometrics Launches DOT Translation Servicehttps://modernod.com/news/digitaloptometrics-launches-dot-translation-service/2482073/DigitalOptometrics announced the launch of “DOT” (DigitalOptometrics Translate), a new translation service that aims to improve patient care. “DOT” is a real-time translation technology that breaks language barriers, allowing eye care professionals to commun
- iuvo BioScience Acquires Promedica International to Expand Ophthalmic Clinical CRO Serviceshttps://modernod.com/news/iuvo-bioscience-acquires-promedica-international-to-expand-ophthalmic-clinical-cro-services/2482070/Partner Research Organization iuvo BioScience announced it has acquired Promedica International (PMI), an ophthalmology-focused clinical CRO. Financial terms of the deal were not disclosed. The companies say the combined organization will support all aspects of opht
- EssilorLuxottica Showcases Nuance Audio Smart Eyewear With Hearing-Aid Solutionhttps://modernod.com/news/essilorluxottica-showcases-nuance-audio-smart-eyewear-with-hearing-aid-solution/2482051/EssilorLuxottica announced it will showcase its consumer technology at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada. The company is a France-based designer, manufacturer, and global distributor of eyecare and eyewear prod
- OrCam Unveils Enhancements for MyEye and Read3 Devices at CEShttps://modernod.com/news/orcam-unveils-enhancements-for-myeye-and-read3-devices-at-ces/2482050/OrCam Technologies, which is focused on personal artificial intelligence (AI) assistive technology platforms, introduced new enhancements for its MyEye and Read3 devices at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada.
- Gentex Acquires eSighthttps://modernod.com/news/gentex-acquires-esight/2482048/Gentex announced the asset acquisition of eSight, a provider of vision enhancement technologies, to develop and manufacture next-generation mobile electronic eyewear that is designed to help people living with visual impairments. The company will feature eSight’s technology at CES 2024, the
- Harrow Partners with Healthcare Market Access Technology Platforms to Support Launch of Vevyehttps://modernod.com/news/harrow-partners-with-healthcare-market-access-technology-platforms-to-support-launch-of-vevye/2482037/Harrow announced that it has partnered with three healthcare technology platforms to expand US availability of dry eye drug Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) ophthalmic solution based on a water-free semifluorinated alkane (
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulationhttps://modernod.com/news/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations-that-restricted-cyclophotocoagulation/2482036/Iridex announced all five Medicare Administrative Contractors (MACs) retired their local coverage determinations (LCDs) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate
- Lupin Receives FDA Approval for Generic Loteprednol Etabonate Ophthalmic Suspensionhttps://modernod.com/news/lupin-receives-fda-approval-for-generic-loteprednol-etabonate-ophthalmic-suspension/2482032/Mumbai, India-based Lupin announced that it has received approval from the FDA for its abbreviated new drug application for Loteprednol etabonate ophthalmic suspension, 0.2%. The formuation is a generic equivalent to the reference listed drug Alrex Ophthalmic Suspension, 0.2%
- UAlbany Scientists Explore New Molecular Tool to Treat Retinal Degenerative Diseasehttps://modernod.com/news/ualbany-scientists-explore-new-molecular-tool-to-treat-retinal-degenerative-disease/2482011/University at Albany scientists at the College of Arts and Sciences’ RNA Institute, in collaboration with a research team from the University of Buffalo’s Jacobs School of Medicine and Biomedical Sciences, have received a 4-year, $1.8 million grant from the National Eye